Equillium announces IDMC recommendation for EQUATOR study to continue

Equillium announced a recommendation from the Independent Data Monitoring Committee, or IDMC, based on its review of the interim results from the Phase 3 EQUATOR study evaluating itolizumab in subjects with acute graft-versus-host disease, or aGVHD. The IDMC reviewed unblinded data on over 100 patients through Day 29 of treatment from the study, with pre-determined futility and efficacy stopping boundaries, and recommended that the study proceed with continued enrollment, without modifications.